• Simplified antibiotic may set the stage

    From ScienceDaily@1:317/3 to All on Mon Jan 31 21:30:44 2022
    Simplified antibiotic may set the stage for antitumor treatments

    Date:
    January 31, 2022
    Source:
    Hiroshima University
    Summary:
    Garden soil houses a variety of bacteria and their natural
    byproducts - - including one that may help halt tumor
    growth. Lankacidins are molecules that can be isolated from
    Strepomyces rochei, a common bacterium in soil. In addition to
    antimicrobial properties, a type of lankacidins, called lankacidin
    C, can inhibit tumor activity in various cancer cell lines,
    including leukemia, melanoma, ovarian and breast cancers. Lankacidin
    C offers a potential foundation on which to design anticancer drugs,
    but its structure is complicated and difficult to manipulate,
    according to an international research group. The same group
    recently identified where antitumor activity is housed on the
    molecule and has now used that information to simplify lankacidin
    as a potential starting point to engineer treatments.



    FULL STORY ========================================================================== Garden soil houses a variety of bacteria and their natural byproducts
    - - including one that may help halt tumor growth. Lankacidins are
    molecules that can be isolated from Strepomyces rochei, a common
    bacterium in soil. In addition to antimicrobial properties, a type of lankacidins, called lankacidin C, can inhibit tumor activity in various
    cancer cell lines, including leukemia, melanoma, ovarian and breast
    cancers. Lankacidin C offers a potential foundation on which to design anticancer drugs, but its structure is complicated and difficult to
    manipulate, according to an international research group. The same group recently identified where antitumor activity is housed on the molecule
    and has now used that information to simplify lankacidin as a potential starting point to engineer treatments.


    ==========================================================================
    They published their results on Jan. 1 in Bioorganic & Medicinal
    Chemistry.

    "Lankacidins have potential antitumor agents, however, their structural modification has somewhat problem due to the presence of complex
    bicyclic ring in lankacidin antibiotics," said paper author Kenji
    Arakawa, associate professor at Hiroshima University's Graduate School
    of Integrated Sciences for Life. "Structural modification of lankacidin
    C, as a mother compound, would be an excellent starting point for
    enhancing antitumor activity through computational prediction." The researchers preliminarily assessed how various components of lankacidin-
    group antibiotics may contribute to its antitumor activity using a computational model, finding that a structural ring of carbon atoms,
    called the delta-lactone ring, may not be essential. According to Arakawa,
    the implication was striking, since the ability to structurally modify lankacidins has been limited by the presence of the delta-lactone ring.

    "In this study, we synthesized lankacyclinone C, a novel lankacidin C
    variant lacking the delta-lactone ring," Arakawa said. "In doing so, we
    solved one major issue of structural function in the lankacidin skeleton,
    the bicyclic structure of the delta-lactone ring, for antitumor activity."
    They used a protein called Orf23 to convert the bicyclic structure with
    the delta-lactone ring to a monocyclic version. A computational model
    predicted that the resulting lankacyclinone C, with a simplified ring,
    would still prove cytotoxic to target cancer cells. Experimental results supported the prediction.

    "Rather than bicyclic lankacidins, structurally simple and flexible
    monocyclic lankacidins may be better substrates for further structural redesigning to improve antitumor activity," Arakawa said.

    According to Arakawa, the researchers plan to further investigate the
    rational design of molecular compounds with the goal of creating the
    ultimate antitumor agents.

    Other contributors include Rukman Muslimin, Natsumi Nishiura and Aiko
    Teshima, Unit of Biotechnology, Division of Biological and Life Sciences, Graduate School of Integrated Sciences for Life, Hiroshima University,
    Japan; Kiep Minh Do, Takeshi Kodama and Hiroyuki Morita, Institute of
    Natural Medicine, University of Toyama, Japan; Cody Wayne Lewis and Gordon Chan, Department of Oncology, Cross Cancer Institute and Cancer Researcher Institute of Northern Alberta, University of Alberta, Canada; and Ahmed
    Taha Ayoub, Medicinal Chemistry Department, Heliopolis University, Egypt.

    Arakawa, Nishiura and Teshima are also affiliated with the Hiroshima
    Research Center for Healthy Aging, Hiroshima University.

    The Japan Society for the Promotion of Science, the Ministry of Scientific Research/Science and Technology Development Fund, the Ministry of
    Education, Culture, Sports, Science and Technology of Japan, the Izaak
    Walton Killam Memorial Scholarship, the Natural Sciences and Engineering Research Council of Canada, the Canadian Institutes of Health and the
    Indonesia Endowment Fund for Education supported this work.

    ========================================================================== Story Source: Materials provided by Hiroshima_University. Note: Content
    may be edited for style and length.


    ========================================================================== Journal Reference:
    1. Rukman Muslimin, Natsumi Nishiura, Aiko Teshima, Kiep Minh Do,
    Takeshi
    Kodama, Hiroyuki Morita, Cody Wayne Lewis, Gordon Chan, Ahmed Taha
    Ayoub, Kenji Arakawa. Chemoenzymatic synthesis, computational
    investigation, and antitumor activity of monocyclic lankacidin
    derivatives. Bioorganic & Medicinal Chemistry, 2022; 53: 116551
    DOI: 10.1016/j.bmc.2021.116551 ==========================================================================

    Link to news story: https://www.sciencedaily.com/releases/2022/01/220131110507.htm

    --- up 8 weeks, 2 days, 7 hours, 13 minutes
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)